---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-002661"
form_type: "8-K"
ticker: "LYRA"
cik: "0001327273"
company_name: "Lyra Therapeutics, Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:04:16.448608+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lyra reports BEACON Phase 2 smell-loss data: 0.87 improvement at week 24 (p=0.026)

## Summary
- BEACON Phase 2 trial: 0.87 improvement in smell loss vs control at week 24 (p=0.026) in patients with impaired smell at baseline.
- Data filed in corporate presentation posted Jan 8, 2024; subset analysis shows statistically significant benefit.
- No safety or additional efficacy details disclosed; further development plans not specified.
- Lyra is a clinical-stage biotech focused on chronic rhinosinusitis therapies.

## SEC filing metadata
- accession: 0000950170-24-002661
- form_type: 8-K
- ticker: LYRA
- cik: 0001327273
- company_name: Lyra Therapeutics, Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1327273/000095017024002661/0000950170-24-002661-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1327273/000095017024002661/lyra-20240108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-002661
- JSON: https://secwatch.observer/filing/0000950170-24-002661.json
- Plain text: https://secwatch.observer/filing/0000950170-24-002661.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.